Clinical trial · Observational
A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province
NCT05130424CI-TRIAL-00055208unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To observe and evaluate the safety and effectiveness of herombopag in the treatment of thrombocytopenia-related diseases in Henan Province
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma;Blood | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Herombopag | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Incidence of adverse events after the treatment of Herombopag
- timeFrame
- From the treatment of Herombopag to 28 days after the end of the medication
- description
- The investigator will observe incidence of adverse events after the treatment of Herombopag, including thrombosis, diarrhea, abnormal liver function and so on.
Secondary outcomes (2)
- measure
- Changes of the platelet counts after the treatment of Herombopag
- timeFrame
- From the treatment of Herombopag to 28 days after the end of the medication
- description
- The investigator will assess the changes of the platelet counts after the treatment of Herombopag。
- measure
- Proportion of patients with platelet transfusion
- timeFrame
- From the treatment of Herombopag to 28 days after the end of the medication
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Thrombocytopenia related diseases; 2. Volunteer to join this study and sign an informed consent form; 3. Clinical evaluation can benefit from Herombopag. Exclusion Criteria: 1. Those who have been confirmed to be allergic to Herombopag and/or its excipients; 2. Pregnant or breastfeeding women; 3. Except for patients with contraindications to Herombopag; 4. Doctors evaluate patients who are not suitable for inclusion.
References
Publications (0)
Data not yet available
No reference posted for this study.